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The aim of this paper is to determine the involvement of tumour necrosis factor-α (TNF-α) and interleukin (IL)-6 in interme-
diate CRPS 1 as locally formed mediators of inﬂammation. In this study, 25 patients with proven CRPS 1 (Bruehl criteria) were
included. All patients participated in one of our earlier studies during the acute stage of their disease. After the disease developed
into an intermediate stage, both the disease activity and the proﬁle of inﬂammatory mediators were reevaluated. Disease activity
and impairment were determined by means of a visual analogue scale, the McGill Pain Questionnaire, the diﬀerence in volume
and temperature between the involved and uninvolved extremities, and the reduction in active range of motion of the involved
extremity. Suction blisters were made on the involved and uninvolved extremities for measurement of IL-6 and TNF-α. A signiﬁ-
cant improvement in signs and symptoms of impairment was found. However, the levels of IL-6 and TNF-α in blister ﬂuid in the
involved extremity versus uninvolved extremity were still signiﬁcantly raised. Although signs and symptoms are signiﬁcantly im-
proved, proinﬂammatory cytokines are still increased in CRPS 1 aﬀected extremities during the intermediate stage of the disease.
This indicates that the initiation and sustained development of the disease are only partially aﬀected by proinﬂammatory cytokines.
Follow-up in the chronic stage is necessary to draw more deﬁnite conclusions about the existence of a supposed relation between
clinical signs and symptoms and the level of proinﬂammatory cytokines.
INTRODUCTION
The complex regional pain syndrome type 1 (CRPS 1)
is a disease occurring in an extremity after an initiating
noxious event, such as a Colles fracture or minor surgery,
which is mainly characterised by spontaneous pain, allo-
dynia,andhyperalgesia.Complexregionalpainsyndrome
type 2 (CRPS 2) develops after a nerve injury. The symp-
toms in CRPS 1 are not limited to the region of a single
peripheral nerve and are generally disproportional to the
inciting event. There is (or has been) evidence of oedema,
disturbed blood ﬂow or abnormal sudomotor activity in
the aﬀected limb. CRPS 1 diagnosis is excluded by the ex-
istenceofconditionsthatwouldotherwiseaccountforthe
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degree of pain and dysfunction. The pathophysiology of
CRPS 1 remains unclear. Several studies suggest a periph-
eral aﬀerent mechanism, others suggest a peripheral ef-
ferent mechanism, or central mechanisms including psy-
chologicalmechanismsorcombinationsofmorethanone
mechanism have been suggested. Evidence for inﬂamma-
tion was shown by Huygen et al; an increase in the levels
of IL-6 and TNF-α in blister ﬂuid of the involved versus
uninvolved extremity in the acute phase suggests a local
inﬂammatory process [1].
T h ec o u r s eo fs y m p t o m si nC R P Sh a sb e e np o o r l y
studied. Classic teaching is that patients aﬄicted with
this disorder progress through three stages, but this is
mainly based on clinical observation rather than scien-
tiﬁc data [2]. In general, the disease is characterised in
the acute stage by symptoms of regional inﬂammation,
which are severe burning pain, muscle spasm, joint stiﬀ-
ness, restricted mobility, rapid hair and nail growth, and
vasospasm that aﬀect colour and temperature of the skin.
The stage is also indicated as the “warm-” type CRPS 1,
due to increased skin temperature as a result of local in-
ﬂammation. In the chronic stage of the disease, changes
in skin and bones become irreversible and pain spreads
throughout the entire limb and a more neuropathy-like2005:6 (2005) Inﬂammatory Cytokines in Intermediate CRPS 1 367
disorder develops. A possible explanation for this alter-
ation during the disease is the development of sensitiza-
tionorplasticityduringtheregionalinﬂammation,which
results in a neuropathic disorder. At that stage, blood
ﬂow and tissue-blood distribution are diminished, partly
caused by disuse of the extremity, usually resulting in a
decreased skin surface temperature, and therefore also in-
dicated as the “cold-” type CRPS 1. In the intermediate
stage of the disease (1-2 years after the initial event), in-
ﬂammatory mediators, neuropathic substances, and va-
soactive agents could play a prominent role. In general, at
that stage of the disease, marked temperature elevations
have been diminished or even normalised [3].
Veldman et al did not observe any temporal trend in
prospective assessment of 829 patients with reﬂex sym-
pathetic dystrophy (RSD), one of the formerly used indi-
cations to describe the disease [4]. Retrospective surveys
completed by CRPS patients with an average pain dura-
tion of over 3 years similarly indicate that CRPS symp-
toms most often tend to remain stable or even improve,
rather than progressively deteriorate [5].
Since a diminution of the clinical symptoms is to be
expected in a certain time course, we hypothesized that
local inﬂammation would only be present during the ini-
tial,acutestageofthedisease,andthereforetheformation
of proinﬂammatory mediators (such as IL-6 and TNF-α)
should be attenuated during the course of the disease. It is
interesting to know whether this decline is correlated with
an improvement in disease activity as measured by regis-
tration of pain, and by the measurement of diﬀerences in
temperature, volume, and mobility of the joints between
the involved and uninvolved extremities.
MATERIALS AND METHODS
Patients
The study was approved by the medical ethical com-
mittee of the Erasmus Medical Centre Rotterdam.
Between April 2001 and February 2004, 66 patients
withCRPS1participatedinseveralstudieseithertoinves-
tigate the pathophysiology or the eﬀects of speciﬁc treat-
ment of CRPS 1 [1, 6, 7].
In retrospect, 6 of 66 patients proved to have CRPS 2.
Fiftyninepatients,whowerenotinvolvedinanystudyfor
atleast6months,werecontactedbytelephoneandmailto
ﬁll in a short questionnaire about their disease; 49 ques-
tionnaires were returned. These latter patients were asked
to participate in a follow-up measurement. For practical
reasons, only patients with CRPS 1 of one upper extrem-
ity were selected (making artiﬁcial blisters in the skin of
the lower extremity is not always as easy). Patients using
corticosteroids and/or immunosuppresives after the ﬁrst
measurement (T0) were also excluded.
Finally, 25 patients with CRPS 1, at the time of the
follow-up study all being in the so-called intermediate
stage of the disease, agreed to participate. All the pa-
tients fulﬁled the CRPS 1 criteria by Bruehl et al at
the ﬁrst measurement, performed shortly after the ini-
tial event which resulted in the development of the dis-
ease [8]. These modiﬁed diagnostic criteria include the
report of at least one symptom in each of the following
categories: (i) hyperesthesia, (ii) temperature asymmetry
and/or skin colour changes and/or skin colour asymme-
try,(iii)oedemaand/orsweatingchangesand/orsweating
asymmetry, and (iv) decreased range of motion and/or
motor dysfunction (weakness, tremor, dystonia) and/or
trophic changes (hair, nail, skin); and must display at least
one sign in two or more of the following categories: (i)
evidence of hyperalgesia (to pinprick) and/or allodynia
(to light touch), (ii) evidence of temperature asymmetry
and/or skin colour changes and/or skin colour asymme-
try,(iii)evidenceoedemaand/orsweatingchangesand/or
sweating asymmetry, and (iv) evidence of decreased range
of motion and/or motor dysfunction (weakness, tremor,
dystonia) and/or trophic changes (hair, nail, skin).
Signs and symptoms of impairment were assessed by
registration of pain, and by the measurement of diﬀer-
ences in temperature, volume, and mobility between the
involved and uninvolved extremities. Blisters were made
with a suction method in order to determine proinﬂam-
matory cytokines in the involved and uninvolved extrem-
ities.
Registrationofpain
The intensity of pain was assessed using a visual ana-
logue scale (VAS) recorded in 0–100 millimetres and
the McGill Pain Questionnaire, Dutch Language Ver-
sion (MPQ-DLV). The MPQ-DLV score was measured by
counting the total number of words chosen from 20 items
[9].
Temperature
Skintemperaturewasmeasuredwithaninfraredtym-
panic probe thermometer (First Temp Genius, Sherwood
Medical, Crawley, Sussex, UK). Temperature was mea-
sured on the dorsal aspect of the hand in a matrix of
5 points. The diﬀerence in mean temperature between
the involved and uninvolved extremities was calculated
[1, 6, 7, 10, 11].
Oedema
Determination of the volume of the hands was as-
sessed by a volumeter, which weighs the amount of water
displaced by the immersion of a body part. The diﬀerence
between the involved and uninvolved extremities was cal-
culated as a percentage of the uninvolved extremity [12].
Mobility
Mobility was assessed by means of measurement of
a c t i v er a n g eo fm o t i o n( A R O M ) .T h eA R O Mi sd e ﬁ n e d
as the arc of motion with muscle power to achieve the
motion of a joint. In the upper extremity, the AROM
was measured for the dorsal/palmar ﬂexion in the wrist,
for the ﬂexion/extension in the metacarpophalangeal and368 Renate J. M. Munnikes et al 2005:6 (2005)
Table 1. Demographic data. Data are presented as median ± interquartile range. Two patients participated in 2 studies. References:
literature on reported eﬀects in CRPS 1.
Patient characteristics Number
Sex (male/female) 6/19
Age at follow-up (years) 54 (49.5–57.5)
Duration of CRPS 1 (months) at ﬁrst measurement 6 (2–12)
Duration of CRPS 1 (months) at follow-up 30 (23–40)
Fracture/trauma/surgery/spontaneous 10/8/6/1
Treatment during the course of the disease (T0-Tf) 12 patients with no speciﬁc treatment/physiotherapy [13]
4 patients with DMSO [14, 15]
5 patients with capsaicin [16]
1 patient with anti-TNF [7]
5 patients with acupuncture [17]
proximal interphalangeal joints of the two most restricted
digits.
The position of the patients and the method of mea-
surement were standardized for each joint, conforming
to the American Society of Hand Therapists clinical as-
sessment recommendations [13] .T h eA R O Mo ft h ei n -
volvedextremitywasmultipliedby100anddividedbythe
AROMontheuninvolvedextremity:thisresultedinaper-
centage of normal mobility. The compounded percentage
was then scored from 1 to 5, indicating a percentage of
mobility: score 1≥95% normal mobility; 2 =94%–85%;
3 =84%–65%; 4 =64%–25%; and 5≤25% normal mobil-
ity. The sum of points was calculated which could range
f r o m5( n o r m a lm o b i l i t y )t o2 5( m o s ta b n o r m a lm o b i l -
ity) [1, 6, 7, 10].
Blisters
Blisters were induced by means of a suction method
[11].A3-wellskinsuctionchamberwaspositionedonthe
skin of the upper extremity, on the dorsal side of the in-
volvedhandandtheﬂexorsideoftheuninvolvedforearm.
A vacuum of 300mm Hg was applied with a At-
moforte 350A aspirator pump (ATMOS Medizintechnik,
Lenzkirch, Germany), which was reduced after 15 min-
utes to 250 mm Hg and again, 15 minutes later, reduced
to 200mm Hg. This negative pressure was maintained for
2t o2 .5 hours. The developed blisters were punctured
andproducedapproximately150µlblisterﬂuidfromeach
side. All samples were stored at −80◦C until analysis
[1, 6, 7, 10, 11].
Laboratoryassays
Blister samples were diluted 4-fold in appropriate cal-
ibrator diluent assay buﬀer for the direct measurement
of cytokines. Cytokine assays were performed following
the manufacturer’s protocol (Pelikine Human ELISA Kits
for IL-6 (M1906) and TNF-α (M1920), CLB, Amsterdam,
the Netherlands). The standard curve ranges and mean
c a l c u l a t e dz e r os i g n a l+3S Df o rI L - 6w e r e0 – 8 0p g / m L
and0.3pg/mL,respectively;andforTNF-α0–1000pg/mL
and 1pg/mL, respectively. The absorbance per well was
measured at 450nm with a Medgenix ELISA reader. Sam-
ple concentrations were calculated using the appropriate
standard calibration lines and the Softmax software of the
reader.
Statisticalanalysis
Because of a nonlinear distribution, the data of cy-
tokine contents in blister ﬂuids were described as median
and interquartile ranges. Comparison of paired samples
was performed with the Wilcoxon signed-ranks test. Sig-
niﬁcance was accepted with a p<0.05 (two-sided).
RESULTS
A group of 25 patients with an intermediate duration
of CRPS 1 (median 30 months, interquartile range 23–40
months)inoneextremitywereexaminedinthefollow-up
of their CRPS; patient characteristics and participation in
previous studies are presented in Table 1.
The signs and symptoms of impairment are described
in terms of pain and diﬀerences in temperature, volume,
and mobility between the involved and uninvolved ex-
tremities during the ﬁrst (T0) and follow-up (Tf) mea-
surement. Diﬀerence in volume, AROM, VAS, and McGill
Pain Questionnaire show a signiﬁcant decrease at Tf com-
pared to T0 (Wilcoxon signed-ranks test, p<0.05). De-
spite a tendency to decrease, the temperature diﬀerence
between the involved and uninvolved extremities during
the ﬁrst (T0) and follow-up (Tf) measurement is not sig-
niﬁcant. Data on these parameters are given in Table 2.
This study showed a signiﬁcant elevation of IL-6 and
TNF-α levels in the involved extremity compared with the
uninvolved extremity in patients with intermediate CRPS
1 at follow-up as was found in the ﬁrst measurement
(Wilcoxon signed-ranks test, p<0.05) [1, 6, 7]. There is
no signiﬁcant diﬀerence in IL-6 and TNF-α levels in both
involved and uninvolved extremities between T0 and Tf.
These data are presented in Table 3 and in Figure 1a (IL-
6) and Figure 1b (TNF-α).
Three patients considered themselves to be cured of
CRPS 1. These are patients 3, 10, and 24 in Figures 1a and
1b. Patient 3 showed a slight decrease in strength. Patient
10, though considering herself as cured, still had signs of2005:6 (2005) Inﬂammatory Cytokines in Intermediate CRPS 1 369
Table 2. Signs and symptoms of impairment in the study population at ﬁrst measurement (T0) and follow-up measurement (Tf).
Data are presented as median ± interquartile range.
N = 25 T0 Tf
Diﬀerence in temperature between involved and uninvolved sides 0.20 .04
(delta T: in ◦C) (−0.36 to +0.75) (−0.57 to +0.34)
Diﬀerence in volume between involved and uninvolved sides 12 −13
(delta V: in % volume uninvolved extremity) (−7t o+ 2 7 .5) (−40.5 to +37)∗
Active range of motion 17 10
(AROM: sum of numbers which express percentage of normal
(11 to 19.5) (8 to 13)∗
mobility, extremity: 5–25: normal mobility–most abnormal)
McGill Pain Questionnaire 11 4
(MPQ: number of counted words that describe pain) (9 to 14) (2 to 8.75)∗
Pain by means of visual analogue scale 60 40
(VAS: 0–100mm: no pain–most pain) (46 to 72) (7.5t o6 5 .5)∗
∗Wilcoxon signed-rank sum test p<0.05.
ﬁbrosis and contracture in the palm of the hand. Light
touch was unpleasant.
Patient 24 had only some minor hypesthesia of the
aﬀected extremity. Nine patients experienced no change
in CRPS and one patient had an increase in symptoms.
Twelve patients reported a decrease of the symptoms.
At physical examination, there was a general improve-
ment of physical signs of CRPS 1 in all 25 patients.
Most patients could be considered as cured with vari-
able light to moderate signs of contracture and weakness.
Only patient 25 had severe allodynia and functional loss
combined with a decrease in temperature of the involved
hand.
DISCUSSION
The involvement of the immunologic system in CRPS
is still a matter of debate. Treatment with radical scav-
engerssuchasdimethylsulfoxide(DMSO),whichinsome
cases proved to be beneﬁcial, suggested the contribution
of an initially occurring inﬂammatory reaction [14, 18].
Our research group found evidence of the involvement
of the immunologic system by the presence of proin-
ﬂammatory cytokines in blister ﬂuid collected in patients
with (sub-)acute CRPS 1 [1]. This may cause activation
and sensitization of primary aﬀerents and, by this mech-
anism, neuropeptide release in the aﬀected body region
(mainly, substance P (SP) and calcitonin gene-related
peptide (CGRP)), thereby resulting in a neurogenic in-
ﬂammation [19].
In intermediate and long-term CRPS 1 patients, there
is no indication of the involvement of these immuno-
logic indices reﬂected in blood samples [20, 21]. In gen-
eral, the sequence of (inﬂammatory) mediators released
during the subsequent processes will result in a cascade
of distinguishing substances which might inﬂuence each
other’s production. The sequential production of neu-
ropeptides, cytokines, chemokines, eicosanoids, nitric ox-
ide, and other vasoactive substances is dependent on cells
involved at certain time intervals of the ongoing process
and crosstalk between migrated cells [3, 18]. So far, lim-
itedinformationisavailableconcerningrepresentativepa-
rameters reﬂecting consecutive stages of this disease. Al-
though in general a warm CRPS 1 is observed during the
initial stage of the disease, not all patients turn into cold
CRPS 1 from the intermediate to the chronic stage of the
disease. Assuming that skin surface temperature not only
reﬂects tissue-blood distribution but also local inﬂam-
mation, based on videothermographic measurements of
the CRPS1 extremity (3), after the initial inﬂammatory
event, a diminished amount of (inﬂammatory) mediators
present in the interstitial ﬂuid would have been expected
during the intermediate stage of the disease.
During this stage of the disease, some signs and symp-
toms, such as volume of the extremity, AROM, McGill
Pain Questionnaire, and VAS pain are signiﬁcantly im-
proved (Table 2), suggesting a spontaneous or treatment-
initiated recurrence of the disease severity. Although a
slight decline of proinﬂammatory cytokines is observed,
these mediators are still increased in CRPS 1 aﬀected ex-
tremities (Table 3, Figures 1 and 2). This indicates that
the initiation and sustained development of the disease is
at least partially aﬀected by proinﬂammatory cytokines.
Diﬀerences in mean temperature during the ﬁrst mea-
surement and the follow-up measurement were not sig-
niﬁcantly decreased. Furthermore, characteristic indica-
tors of skin surface temperature were not directly related
to blister ﬂuid levels of the cytokines IL-6 and TNF-α.
This suggests a complex mechanism in which a number
of cells and mediators play a role. At this stage, the most
prominent cell source to generate these cytokines could
be monocytes, tissue macrophages, and mast cells [6]. Al-
though the cell counts will not dramatically change dur-
ing this stage of the disease, both the activation and the
cell-cell interaction could have changed, due to ﬂuctuat-
ing levels of neuropeptides. On the other hand, long-term
disuseorimmobilitywillcertainlyaﬀecttheaccumulation
of peptides secreted by the nerves, which could contribute370 Renate J. M. Munnikes et al 2005:6 (2005)
Table 3. Data on IL-6 and TNF-α levels in blister ﬂuid in the involved and uninvolved extremities at ﬁrst measurement (T0) and
follow-up measurement (Tf). Data are presented as median ± interquartile range.
N = 25 T0 Tf
Uninvolved Involved Uninvolved Involved
IL-6 (pg/mL) 3( 1 .7–18.5) 41 (7.5–98)∗ 2.1( 1 .2–4.9) 24.3( 3 .5–165.6)∗
TNF-α (pg/mL) 5.9( 3 .1–32.5) 26 (12–85)∗ 7.8( 5 .1–16.7) 31.6( 7 .7–90.4)∗
∗Wilcoxon signed-rank sum test p<0.05.
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Figure 1. Individually plotted values of TNF-α (logarithmic
scale) in involved (closed symbols) and uninvolved sides (open
symbols) of all CRPS 1 patients, (a) at ﬁrst measurement (T0)
and (b) at follow-up measurement (Tf). Note that on T0 (acute
stage), 19 patients displayed an increased value in the involved
versus the uninvolved extremity, whereas on Tf (intermediate
stage), still 16 patients displayed an increased value.
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Figure 2. Individually plotted values of IL-6 (logarithmic scale)
in involved (closed symbols) and uninvolved sides (open sym-
bols) of all CRPS 1 patients, (a) at ﬁrst measurement (T0) and
(b) at follow-up measurement (Tf). Note that on T0 (acute
stage), 23 patients displayed an increased value in the involved
versus the uninvolved extremity, whereas on Tf (intermediate
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to allodynia and hyperalgesia, but also vasomotor, sudo-
motor, and motor/trophic signs and symptoms.
In our results, both the ranges of data found and the
abnormal distribution of cytokine levels in involved and
involved extremities are remarkable (Figures 1 and 2). Al-
though all patients were accurately included according to
the criteria of by Bruehl et al [8], we cannot entirely ex-
clude contamination of our study population. Inclusion
ofsubpopulations whichfulﬁlthemaincriteria couldalso
inﬂuence the outcome of the results [22, 23].
A further follow-up of our selected CRPS 1 patients
fromtheintermediatestageintothechronicstage(greater
than 4 years) is therefore needed to draw more deﬁnite
conclusions about the existence of a supposed relation
between clinical signs and symptoms and local levels of
proinﬂammatory cytokines in interstitial ﬂuid. Further-
more, an extension of the tested pallet of cytokines should
be considered in order to unravel the contribution of
speciﬁc cytokines (pro- and anti-inﬂammatory cytokines,
Th1/Th2 cell-derived cytokines, chemokines) during the
whole course of the disease. More insight in the time-
related contribution of speciﬁc cytokines will enable the
selectiveuseofimmunosuppressives[7,18]orthespeciﬁc
development of disease-modifying agents.
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